Ettinger B
Am J Obstet Gynecol. 1987 May;156(5):1298-303. doi: 10.1016/0002-9378(87)90168-2.
The most widely recognized reason for prescribing estrogen for menopausal women is for control of symptoms. Estrogen effectively reduces the vasomotor, somatic, and associated psychologic components of the menopausal syndrome. Recently, however, the role of estrogen in the prevention of disease, particularly osteoporosis, urogenital atrophy, and atherosclerotic cardiovascular disease, has prompted consideration of this treatment for a more long-term goat. Bone loss occurring after menopause can be prevented by the use of estrogen; this significantly reduces the morbidity and mortality of associated fractures. Atrophic changes, which can occur earlier in the menopause than previously recognized, also respond to estrogen treatment. Atherosclerotic risk profiles are improved by estrogen replacement: blood pressure is lowered, total cholesterol and low-density lipoprotein cholesterol are reduced, and high-density lipoprotein cholesterol is increased. Most studies have found that the incidence of angina or myocardial infarction is lower in estrogen users than in nonusers, and overall mortality rates from cardiovascular disease appear to be reduced as well.
为绝经后女性开雌激素处方最广为人知的原因是控制症状。雌激素能有效减轻绝经综合征的血管舒缩、躯体及相关心理症状。然而,近来雌激素在预防疾病,尤其是骨质疏松症、泌尿生殖系统萎缩和动脉粥样硬化性心血管疾病方面的作用,促使人们考虑将这种治疗用于更长期的目标。绝经后发生的骨质流失可通过使用雌激素来预防;这能显著降低相关骨折的发病率和死亡率。萎缩性变化在绝经时比以前认为的更早出现,也对雌激素治疗有反应。雌激素替代可改善动脉粥样硬化风险状况:血压降低,总胆固醇和低密度脂蛋白胆固醇减少,高密度脂蛋白胆固醇增加。大多数研究发现,使用雌激素者心绞痛或心肌梗死的发生率低于未使用者,而且心血管疾病的总体死亡率似乎也有所降低。